JP2012530779A5 - - Google Patents

Info

Publication number

JP2012530779A5

JP2012530779A5 JP2012517622A JP2012517622A JP2012530779A5 JP 2012530779 A5 JP2012530779 A5 JP 2012530779A5 JP 2012517622 A JP2012517622 A JP 2012517622A JP 2012517622 A JP2012517622 A JP 2012517622A JP 2012530779 A5 JP2012530779 A5 JP 2012530779A5

Authority

JP

Japan

Prior art keywords

pharmaceutical composition

composition according

group

compound

fatigue

Prior art date

2010-06-21

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 150000001875 compounds Chemical class 0.000 claims description 12
• 239000008194 pharmaceutical composition Substances 0.000 claims 17
• 206010016256 fatigue Diseases 0.000 claims 6
• 125000004432 carbon atom Chemical group C* 0.000 claims 5
• 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 5
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
• 125000000217 alkyl group Chemical group 0.000 claims 3
• 150000002148 esters Chemical class 0.000 claims 3
• 229940002612 prodrug Drugs 0.000 claims 3
• 239000000651 prodrug Substances 0.000 claims 3
• 150000003839 salts Chemical class 0.000 claims 3
• 125000003118 aryl group Chemical group 0.000 claims 2
• 201000010099 disease Diseases 0.000 claims 2
• 208000035475 disorder Diseases 0.000 claims 2
• 238000002651 drug therapy Methods 0.000 claims 2
• 125000001072 heteroaryl group Chemical group 0.000 claims 2
• 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
• 125000004430 oxygen atom Chemical group O* 0.000 claims 2
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
• 208000030507 AIDS Diseases 0.000 claims 1
• 208000024827 Alzheimer disease Diseases 0.000 claims 1
• 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 1
• 208000000094 Chronic Pain Diseases 0.000 claims 1
• 208000001640 Fibromyalgia Diseases 0.000 claims 1
• 206010028980 Neoplasm Diseases 0.000 claims 1
• 208000002193 Pain Diseases 0.000 claims 1
• 208000018737 Parkinson disease Diseases 0.000 claims 1
• 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
• 125000003545 alkoxy group Chemical group 0.000 claims 1
• 230000001430 anti-depressive effect Effects 0.000 claims 1
• 239000000935 antidepressant agent Substances 0.000 claims 1
• 229940005513 antidepressants Drugs 0.000 claims 1
• 125000003710 aryl alkyl group Chemical group 0.000 claims 1
• 238000010322 bone marrow transplantation Methods 0.000 claims 1
• 229910052794 bromium Inorganic materials 0.000 claims 1
• 201000011510 cancer Diseases 0.000 claims 1
• 238000002512 chemotherapy Methods 0.000 claims 1
• 229910052801 chlorine Inorganic materials 0.000 claims 1
• 125000000753 cycloalkyl group Chemical group 0.000 claims 1
• 229910052731 fluorine Inorganic materials 0.000 claims 1
• 125000005843 halogen group Chemical group 0.000 claims 1
• 125000000623 heterocyclic group Chemical group 0.000 claims 1
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
• 229910052740 iodine Inorganic materials 0.000 claims 1
• 239000000203 mixture Substances 0.000 claims 1
• 201000006417 multiple sclerosis Diseases 0.000 claims 1
• 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
• 201000008482 osteoarthritis Diseases 0.000 claims 1
• 238000001959 radiotherapy Methods 0.000 claims 1
• 230000001225 therapeutic effect Effects 0.000 claims 1
• 125000005309 thioalkoxy group Chemical group 0.000 claims 1
• 230000009529 traumatic brain injury Effects 0.000 claims 1
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
• AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 2
• PCTMTFRHKVHKIS-BMFZQQSSSA-N (1s,3r,4e,6e,8e,10e,12e,14e,16e,18s,19r,20r,21s,25r,27r,30r,31r,33s,35r,37s,38r)-3-[(2r,3s,4s,5s,6r)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,30,31,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10 Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2.O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 PCTMTFRHKVHKIS-BMFZQQSSSA-N 0.000 description 2
• AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 2
• 229940079593 drug Drugs 0.000 description 2
• 239000003814 drug Substances 0.000 description 2
• 229960002296 paroxetine Drugs 0.000 description 2
• 239000000902 placebo Substances 0.000 description 2
• 229940068196 placebo Drugs 0.000 description 2
• 230000003340 mental effect Effects 0.000 description 1
• 230000008450 motivation Effects 0.000 description 1